Kwality Pharmaceuticals Ltd (KPL) is currently trading at 3,632.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Kwality Pharmaceuticals is an integrated Indian finished‑dosage pharmaceutical manufacturer producing oral liquids, tablets, capsules, sterile powders and injectables, with five operational manufacturing units and a sixth hormone unit slated to commence commercial activities in November 2026. The company has built a regulatory and export footprint with multiple international certifications (EU‑GMP, PIC/S and approvals from SFDA, INVIMA, ANVISA) and reported registration activity across LATAM, MENA and other ROW markets, claiming distribution reach into roughly 80 countries in FY2026. Kwality is running a product and dossier heavy strategy: management highlighted about 40 BE (bioequivalence) programmes, a pipeline of ~200–250 target products for filings across 60–80 countries, and 60–70 registrations achieved in recent quarters, supporting recurring quarterly registration cadence and export revenue growth. Near‑term commercial catalysts cited include commercializing Unit 5 biologics (erythropoietin), Unit 6 hormone capacity, completion of multiple BE studies and niche injectable launches (liposomal Ampho B, Octreotide LAR, Leuprolide), supported by a planned INR185–195 crore capex and partnerships for regional fill‑finish manufacturing. On financials management targets margin expansion and scale: recent gross margin commentary was about mid‑50s percent trending toward a mid‑ to high‑40s normalized level for larger revenue base, EBITDA margin guidance aims toward ~30% as revenue approaches INR1,000 crores, with receivables targeted to fall to roughly 155–170 days.

Over the past 52 weeks, Kwality Pharmaceuticals Ltd has traded between a low of ₹828.80 and a high of ₹3,866.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Kwality Pharmaceuticals Ltd has a market capitalization of approximately 3,668.35. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Kwality Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 45.26 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 3,668.35 Cr, Kwality Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Kwality Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Kwality Pharmaceuticals Ltd is 45.26. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Q1FY27 consolidated revenue rose 46% YoY to ₹162 crore, and net profit (PAT) increased 119% YoY to ₹26 crore.